Company intelligence / Profile preview
RiboX Therapeutics
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
RiboX Therapeutics is the first company globally to dose a patient in a clinical trial with a circular RNA therapy. Its lead candidate RXRG001 is in Phase I/IIa trials for radiation-induced xerostomia and hyposalivation. The therapy aims to address significant unmet needs in patients suffering from side effects of head and neck cancer radiotherapy. The company’s pipeline also includes programs targeting monogenic rare, autoimmune, and metabolic disorders[4][5].
- Therapeutic areas
- OncologyMetabolic DisordersImmunologyRare DiseasesOther
- Modalities
- Circular RNA therapeutics (circRNA)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on RiboX Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RiboX Therapeutics.